Related Experiment Video

Updated: May 25, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Number of microparticles generated during acute myocardial infarction and stable angina correlates with platelet

Ewa Stępień1, Elżbieta Stankiewicz, Jarosław Zalewski

  • 1Department of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland. estepien@cm-uj.krakow.pl

Archives of Medical Research
|February 7, 2012
PubMed
Abstract

Insights

Patients with acute myocardial infarction (AMI) show higher microparticle (MP) counts, particularly from platelets, linked to inflammation. This suggests platelet, monocyte, and endothelial cell interactions are key in myocardial ischemia.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Immunology

Background:

  • Elevated circulating microparticles (MPs) are observed in acute myocardial infarction (AMI) and coronary artery disease.
  • Platelet activation and inflammation are recognized during AMI and stable angina (SA).

Purpose of the Study:

  • To investigate the origin and count of MPs in AMI and SA patients.
  • To determine the relationship between MP levels and markers of inflammation and platelet activation.

Main Methods:

  • Flow cytometry was used to quantify platelet, monocyte, and endothelial MPs, along with surface P-selectin.
  • Plasma levels of P-selectin, soluble CD40 ligand (sCD40L), and interleukin-6 (IL-6) were measured using ELISA.

Main Results:

  • Total MP counts were significantly higher in AMI patients (38,750 counts/μl) and SA patients (29,715 counts/μl) compared to controls (12,765 counts/μl).
  • AMI patients exhibited higher levels of total and platelet-derived MPs (tissue factor-positive) than SA patients.
  • Soluble P-selectin levels were elevated in AMI patients compared to SA patients, with significant correlations observed between total MP count, specific MP types, and P-selectin expression in AMI.

Conclusions:

  • Platelet activation in AMI is associated with increased MP generation from platelets, monocytes, and endothelial cells.
  • These findings suggest complex interactions between platelets, monocytes, and endothelial cells are crucial in the pathogenesis of myocardial ischemia.

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...